Dublin, Ireland, 10 September 2012 - ICON plc (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the expansion of its US and UK bioanalytical facilities to meet the growing demand for biomarker and cell-based assay services.
ICON has increased its bioanalytical laboratories in Whitesboro, New York, and Manchester, UK, by 7,000 and 4,000 square feet respectively. The expansions allow ICON to house dedicated immunoassay laboratories at each facility for biomarker testing and cell-based assays. Operating since 1988, ICON’s Whitesboro facility already features multiple wet laboratories and instrument laboratories for small and large molecules, including a specially designed hazardous lab for the analysis of HIV & Hepatitis B infected samples. Similarly, ICON’s Manchester laboratory has provided bioanalytical support for both small and large molecule studies for almost 30 years and is located close to ICON's hospital-based Clinical Pharmacology Unit in Manchester.
“We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors,” commented Brian O’Dwyer, Senior Vice President of Global Bioanalytical Services, ICON Development Solutions. “In particular, the expansion of our dedicated biomarker testing laboratories allows us to support biomarker development programs across multiple testing platforms globally.”
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has 9,200 employees, operating from 82 locations in 40 countries.